<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Menopausal hormone therapy (MHT) use has been quite consistently associated with a decreased <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> risk; however, data regarding <z:mpath ids='MPATH_270'>adenomas</z:mpath>, types of MHT, or <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> site are limited </plain></SENT>
<SENT sid="1" pm="."><plain>We investigated associations between MHT use and colorectal <z:mpath ids='MPATH_270'>adenoma</z:mpath> and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risks within the prospective E3N cohort study </plain></SENT>
<SENT sid="2" pm="."><plain>In the <z:mpath ids='MPATH_270'>adenoma</z:mpath> study, we analyzed the 13,402 postmenopausal women who underwent a colonoscopy during follow-up (1993-2002), including 1,109 who were diagnosed a first colorectal <z:mpath ids='MPATH_270'>adenoma</z:mpath> </plain></SENT>
<SENT sid="3" pm="."><plain>In the <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> study, 525 out of 77,375 postmenopausal women developed a <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> as the first <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignant tumour</z:e> during follow-up (1992-2008) </plain></SENT>
<SENT sid="4" pm="."><plain>Ever use of MHT was not significantly associated with colorectal <z:mpath ids='MPATH_270'>adenoma</z:mpath> risk [Hazard Ratio (HR) = 1.13, 95 % Confidence Interval (CI) = 0.99, 1.29], nor with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> risk (HR = 0.86, 95 % CI = 0.71, 1.04) </plain></SENT>
<SENT sid="5" pm="."><plain>However, ever use of <z:chebi fb="1" ids="50114">estrogens</z:chebi> alone was associated with risks of colorectal <z:mpath ids='MPATH_270'>adenoma</z:mpath> and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> in opposite directions (HR = 1.22, 95 % CI = 1.05, 1.41 and HR = 0.72, 95 % CI = 0.56, 0.94 respectively) </plain></SENT>
<SENT sid="6" pm="."><plain>Associations were strongest for non-advanced, and for left colon <z:mpath ids='MPATH_270'>adenomas</z:mpath> </plain></SENT>
<SENT sid="7" pm="."><plain>Duration, recency of use, type of progestagen or route of <z:chebi fb="0" ids="50114">estrogen</z:chebi> administration were not associated with <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumour</z:e> risk, nor was the use of <z:chebi fb="0" ids="50114">estrogen</z:chebi>-progestagen MHT </plain></SENT>
<SENT sid="8" pm="."><plain>The association between <z:chebi fb="1" ids="50114">estrogens</z:chebi> alone and <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> risk was only observed in women with previous colonoscopy(ies), but the P value of the interaction test between <z:chebi fb="1" ids="50114">estrogens</z:chebi> alone use and history of colonoscopy was 0.06 </plain></SENT>
<SENT sid="9" pm="."><plain>Our data suggest a complex relationship between MHT use, <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumour</z:e> risk and screening strategies, which deserves further investigations in other settings </plain></SENT>
</text></document>